Company profile for Altay Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Altay is a team of scientists with expertise in transcription factor biology and clinical drug development. We believe in an integrated approach to drug development that includes biochemical assays, next generation computational biology and chemoproteomics. Our mission is to develop more specific and safer therapies to extend the lives of patients.Altay Therapeutics is located in MBC Biolabs in San Carlos in the heart of the s...
Altay is a team of scientists with expertise in transcription factor biology and clinical drug development. We believe in an integrated approach to drug development that includes biochemical assays, next generation computational biology and chemoproteomics. Our mission is to develop more specific and safer therapies to extend the lives of patients.Altay Therapeutics is located in MBC Biolabs in San Carlos in the heart of the scientific and entrepreneurial hub. We are near world-class research organizations such as the Gladstone Institute, Stanford University, University of California San Francisco and their core facilities.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
San Francisco, California
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/astellas-and-mbc-biolabs-announce-2023-future-innovator-prize-awarded-to-tippingpoint-biosciences-and-altay-therapeutics-302013297.html

PR NEWSWIRE
12 Dec 2023

Drugs in Development

read-more
read-more

Details:

The investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease-modifying treatment.


Lead Product(s): Undisclosed

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: DiscoveryProduct Type: Undisclosed

Sponsor: SOLVE FSHD

Deal Size: $3.0 million Upfront Cash: Undisclosed

Deal Type: Financing September 21, 2022

blank

01

IPhEB Russia
Not Confirmed
IPhEB Russia
Not Confirmed

Details : The investment will support Altay Therapeutics’ unique approach to finding an inhibitor of DUX4, a key transcription factor implicated in FSHD, that could provide an effective disease-modifying treatment.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

September 21, 2022

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty